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ABSTRACT
Background: Hydromorphone is a potent -opioid selective agonist that has
n onset time within 5 minutes and reaches peak effect between 10 and 20 minutes.
owever, it may show immediate analgesic effect to rocuronium-induced pain
ecause of its peripheral analgesic property and also may attenuate noxious stimuli
rom tracheal intubation during induction. The opioid receptors are known to be
resent in peripheral sensory nerve terminals as well as in the dorsal root ganglion and
he central terminal of primary afferent nerves. Therefore, we hypothesized that
ydromorphone may be considered a potent pretreatment or adjuvant drug during
he induction of anesthesia with its peripherally and centrally mediated analgesia.
Objective: The aim of this study was to compare the effects of pretreatment
ith hydromorphone in reducing rocuronium-induced withdrawal movements and
emodynamic changes during tracheal intubation with the effects of fentanyl and
ormal saline.
Methods: In this double-blind, randomized, controlled study, consecutive
adult patients aged 20 to 70 years who were scheduled to undergo general anesthesia
for elective gastric or colorectal surgery at the Samsung Seoul Hospital (Seoul,
Republic of Korea) were randomly assigned to receive 5 mL hydromorphone 0.03
mg/kg or fentanyl 2 g/kg or normal saline. Thirty seconds after administering the
tudy drug, anesthesia was induced with 2.5% thiopental sodium 5 mg/kg. After loss
f consciousness, rocuronium 0.6 mg/kg was injected and immediate withdrawal
ovements were recorded. Two minutes after rocuronium injection, tracheal intu-
ation was performed and hemodynamic changes were observed.
Results: A total of 194 patients were enrolled, with 65 in the hydromorphone
group, 67 in the fentanyl group, and 62 in the saline group. The overall incidence of
withdrawal movements was significantly lower in the hydromorphone group (2
patients; 3.1%) and the fentanyl group (5 patients; 7.5%) (both, P  0.001) than in
the saline group (36 patients; 58.1%). The mean arterial pressure (MAP) and heart
rate (HR) after intubation (median [interquartile range]) in the fentanyl group (101.5
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S.H. Lee et al.[84115] mm Hg; 93.5 [82102 ] beats per minute [bpm]) and the hydromor-
phone group (93.0 [83106] mm Hg; 90.0 [86.393.6] bpm) were significantly
lower than these measures in the saline group (111.5 [105123] mm Hg; 103.5
[96113] bpm) (fentanyl group MAP and HR, P  0.001; hydromorphone group
MAP and HR, P  0.001).
Conclusions: Pretreatment with hydromorphone and fentanyl may have
similar effectiveness in reducing withdrawal movements in response to rocuronium
injection pain and inducing immediate general anesthesia. (Curr Ther Res Clin Exp.
2011;72:36-48) © 2011 Elsevier HS Journals, Inc. All rights reserved.
Key words: hydromorphone, induction of anesthesia, injection pain, rocuro-
nium, withdrawal movement.
INTRODUCTION
Hydromorphone, a potent -opioid selective agonist with a systemic analgesic onset
ime of 5 minutes and peak effect time within 10 to 20 minutes, has been used widely
or the management of acute postoperative and cancer-related pain.
Opioid receptors are known to be present in peripheral sensory nerve terminals as
ell as in the dorsal root ganglion and the central terminal of primary afferent
erves.1,2 In this regard, opioids with longer blood-brain equilibrium and hysteresis
(ie, the time lag between peak concentration in the plasma and the effect site) may
show immediate analgesic effect via the peripheral opioid receptors at the veins,3
unlike their known delayed onset of action.
The peripherally mediated immediate analgesic property of hydromorphone may
work to reduce intravenous rocuronium injection pain by inhibiting the activation of
the peripheral nociceptors,4,5 and, with its centrally mediated analgesic effect, may
lso produce earlier systemic effect than expected. Therefore, we investigated the
ffectiveness of hydromorphone as a pretreatment drug to reduce the withdrawal
ovements in response to injection of rocuronium and to attenuate hemodynamic
hanges to tracheal intubation compared with that of fentanyl and saline.
PATIENTS AND METHODS
This double-blind, randomized, controlled study was conducted at the Samsung Seoul
Hospital, Samsung Medical Center in Seoul, Korea. This study was approved by the
Samsung Seoul Medical Center’s institutional review board (No. 2008-06-051) and
was registered in the Australian New Zealand Clinical Trials Registry (ANZCTR,
ACTRN12610000316000). Written, informed consent was obtained from all sub-
jects. Patients aged 20 to 70 years who had an American Society of Anesthesiologists
physical status I or II and were undergoing general anesthesia for elective gastric or
colorectal surgery from August 2008 to January 2009 were enrolled consecutively in
this study. Enrollment of patients was evaluated through preanesthetic rounds and
determined by 2 anesthesiologists (E.Y.J. and B.S.S.). Patients with a history of
hypertension were included in the study only if confirmed to be of medically
well-controlled status with blood pressure 140/90 mm Hg with or without anti-
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Current Therapeutic Researchhypertensive medication.6,7 These patients were instructed to continue treatment
ven on the day of surgery. The exclusion criteria were as follows: known allergy and
ontraindication to opioids; history of diabetes mellitus, asthma, or neurological
eficit; pregnancy; or use of analgesics or sedatives within the 24 hours before surgery.
andom allocation of patients into 1 of 3 groups to receive 5 mL of either IV
ydromorphone hydrochloride* 0.03 mg/kg (n  65) or IV fentanyl citrate 2 g/kg
(n  67; Gu Ju Pharm, Seoul, Korea) or IV saline (n  62; sodium chloride, Joong
ae Pharm, Seoul, Korea) was facilitated by using a computer-generated random
umber concealed in an envelope. One of 2 anesthesiologists (S.Y.L. and W.S.S.)
nsealed the envelope in a preparatory room outside the operating theater and
repared the drug or placebo (normal saline) in a syringe accordingly, in the absence
f the study participants. The syringes for both study drug and placebo were
dentical, labeled “study drug” to conceal treatment group allocation. The anesthe-
iologist (S.Y.L. or W.S.S.) who prepared the drug syringe then handed it over to the
nesthesiologists in the operating room, blinded to the treatment allocation, to carry
ut the induction of anesthesia. The anesthesiologists (S.Y.L. and W.S.S.) who
repared the study drug syringes did not participate in the induction of anesthesia
nd left the operating room. The patient and 2 anesthesiologists carrying out the
nduction and recording the outcomes were all blinded to treatment group. The
yringes were stored at room temperature.
Premedication was not administered before surgery. On arrival at the operating
oom, the intravenous cannulation site and its patency were confirmed by the
nesthesiologist. Patients with intravenous cannulation located elsewhere than at
he veins of the forearm were excluded from the study. All patients received
ontinuous electrocardiography, noninvasive arterial pressure, capnography, and
nd-tidal sevoflurane monitoring. All drugs were injected through the proximal
ubber port connected to the intravenous cannula with a free flow of intravenous
actated Ringer solution. During preoxygenation with 100% oxygen, the study
rug was injected over 30 seconds, and an investigator blinded to the study drug
bserved for signs of adverse events, such as apnea and coughing for 30 seconds,
nd questioned patients about adverse events just before injection of thiopental
odium. Then, 2.5% thiopental sodium 5 mg/kg was injected over 5 seconds.
fter loss of consciousness and eyelash reflexes, when the appropriate end-tidal
arbon dioxide curve appeared on capnography upon trial of mask ventilation
ith inspired oxygen fraction 1.0, rocuronium 0.6 mg/kg was injected over 5
econds. The time interval between the study drug injection and rocuronium
njection was set at 90 seconds in all patients. Two anesthesiologists, the one
ho administered the study drug and another to conduct anesthetic induction,
ssessed the patient response during and immediately after rocuronium injection.
he 2 investigators were educated beforehand to grade patients’ responses ac-
ording to the scale proposed by Shevchenko and colleagues8: 1  no movement;*Trademark: Dilid® (Hana Pharm Co, Ltd, Seoul, Korea)
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S.H. Lee et al.2  movement at the wrist only; 3  movement/withdrawal involving the arm
only (elbow/shoulder); 4  generalized response, withdrawal or movement in
more than 1 extremity.
Sevoflurane was started after the rocuronium injection and was adjusted to main-
tain an end-tidal concentration of 2.5 to 3.0 vol% in 100% oxygen. Two minutes
after the rocuronium injection, the anesthesiologist, who had more than 4 years of
experience in anesthetic practice, performed tracheal intubation and applied con-
trolled ventilation to maintain normocarbia without ballooning the cuff for 1 minute
to avoid stimulation. Patient movement and status of vocal cord relaxation were
observed during tracheal intubation. Anesthesia was maintained with sevoflurane
(end-tidal concentration of 2 to 3 vol%). The time interval between the study drug
injection and intubation was designed to be within 3 to 4 minutes in all patients. The
intubation time, defined as the time from mouth opening to obtaining the appro-
priate capnographic trace, was measured in all patients. The mean arterial pressure
(MAP) and heart rate (HR) were measured on arrival at the operating room, 1 minute
before intubation, and 1 minute after tracheal intubation. If there was an increase in
HR (40% in baseline) and/or increased blood pressure with ST change in electro-
cardiography after intubation, IV esmolol (0.3 mg/kg) was available for administra-
tion.
Statistical Analysis
Statistical analyses were carried out using SPSS 12.0 for Windows (SPSS Inc,
hicago, Illinois). The data are reported as mean (SD), median (interquartile range),
r number (proportion) of patients. Patient characteristics and intravenous cannula-
ion sites were compared using 2 test, Fisher exact test, Kruskal-Wallis test, or
-way ANOVA where appropriate. The incidence of withdrawal movements was
nalyzed using Fisher exact test. The changes in MAP and HR within each group
rom the baseline to before and after tracheal intubation were analyzed by repeated-
easures ANOVA with Bonferroni adjustment.
The hemodynamic parameters among groups, including MAP and HR differences
efore and after intubation, were compared using Kruskal-Wallis test with post hoc
nalysis by Tukey test using ranking. P value was corrected by Bonferroni adjustment
ecause of multiple testing. The incidence of patient movements and the status of
ocal cord relaxation during tracheal intubation were analyzed using 2 test and
isher exact test, respectively. The intubation time was compared using Kruskal-
allis test with post hoc analysis by Tukey test using ranking.
The number of patients in the study was determined based on a pilot study, with
n estimated incidence of 45% and 15% withdrawal movement in the saline and
ydromorphone groups, respectively. At least 53 patients were required for each
roup to achieve a 30% reduction in the withdrawal movement at the significance
evel of 5% and power of 90%, and considering the possibility of unanticipated
xclusions (10%). P  0.05 was considered significant.
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A total of 194 patients (hydromorphone group, n  65; fentanyl group, n  67; and
saline group, n  62) were enrolled consecutively between August 2008 and January
2009. Among the 194 patients, 3 patients in the fentanyl group and 1 patient in the
saline group did not complete the study because they met exclusion criteria during
the study process. Exclusion criteria were patients with laryngeal view grade 3 or 4
with no visualization of the vocal cords during tracheal intubation,9 or any other
conditions that would affect vocal cord assessment such as vocal cord spasm, and
patients with an intravenous route other than the forearm. One patient (fentanyl
group) had a percutaneously inserted central catheter instead of a peripheral intra-
venous line, another developed vocal cord spasm (saline group), and 2 patients
(fentanyl group) did not show the vocal cords during intubation. Therefore, 190
patients (hydromorphone group, n  65; fentanyl group, n  64; and saline group,
n  61) (mean [SD] age, 54.6 [10.3] years; height, 163.2 [8.0] cm; weight, 62.1
[9.7] kg) completed the study.
However, for an intent-to-treat analysis, the 194 initially enrolled patients were
analyzed. Figure 1 summarizes the enrollment, randomization, and subsequent
exclusion process. This randomized trial was carried out and reported in accordance
to the CONSORT statement10 and the CONSORT explanation and elaboration
ocument.11 The patients’ characteristics were similar in all groups (Table I). The
ntravenous cannulation sites at the forearm were similar in all 3 groups. The most
ommon intravenous cannulation site was the cephalic vein. The number of patients
ith intravenous cannulation at the cephalic vein were 45, 42, and 46 in the
ydromorphone, fentanyl, and saline groups, respectively. The next most common
ites were accessory cephalic vein, basilic vein, and median antebrachial vein. An
8-gauge intravenous cannula was used for all patients except 1 patient in the saline
roup who had a 20-gauge intravenous line.
Table II lists the incidence and grade of the withdrawal movements. The overall
ncidence of withdrawal movements was significantly lower in the hydromorphone
roup (2 patients; 3.1%) and the fentanyl group (5 patients; 7.5%) (both, P 0.001)
han in the saline group (36 patients; 58.1%). The incidence of wrist, arm, and
eneralized movements was higher in the fentanyl group (1.5%, 3.0%, and 3.0%,
espectively) than in the hydromorphone group (1.5%, 0%, and 1.5%, respectively),
ut without statistical significance.
Figure 2 presents MAP and HR variables. There were statistically significant
hanges in MAP and HR from baselines after intubation in all groups except changes
n MAP after intubation in the hydromorphone group. MAP and HR (median
interquartile range]) after intubation in the fentanyl group (101.5 [84115] mm
g; 93.5 [82–102] bpm) and the hydromorphone group (93.0 [83–106] mm Hg;
0.0 [86.393.6] bpm) were significantly lower than those in the saline group
111.5 [105–123] mm Hg; 103.5 [96–113] bpm) (fentanyl group MAP and HR,
 0.001; hydromorphone group MAP and HR, P  0.001). Changes in MAP
before and after intubation were significant in the fentanyl and hydromorphone
groups compared with those in the saline group (both, P  0.002). Changes in HR
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compared with the saline group. (P 0.006). No patients required administration of
V esmolol after intubation.
Table III shows the incidence of patient movements, status of vocal cord relax-
tion during tracheal intubation, and intubation time. No significant between-group
ifferences were found in the incidence of movements during intubation (12 patients
Figure 1. CONSORT flowchart for patient allocation and participation in this study.18.5%] in the hydromorphone group; 12 [17.9%] in the fentanyl group; and 20
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Current Therapeutic Research[32.3%] in the saline group). The status of vocal cord relaxation during tracheal
intubation was similar in all groups (full/partial relaxation: 59/6 patients [91%/9%]
in the hydromorphone group; 61/5 [91%/9%] in the fentanyl group; and 52/9
[85%/15%] in the saline group). The intubation time (median [interquartile range])
in the hydromorphone group (15.0 [1418] sec), fentanyl group (15.0 [1318] sec),
and saline group (17.0 [1520] sec) were significantly different in the Kruskal-
Wallis test (P  0.032) but without intergroup differences in the Tukey test with
ranking.
DISCUSSION
This study suggests that hydromorphone may be as effective as fentanyl as a pre-
treatment drug in reducing withdrawal movements due to rocuronium injection pain
and inducing general anesthesia without delay.
Hydromorphone has 5 to 7 times more potent analgesic efficacy than morphine,
with a similar or lower incidence of adverse effects.12,13 This opioid is most com-
only used for treating chronic cancer-related pain14,15 but it also has equivalent
Table I. Patients’ characteristics (N  194).*
Hydromorphone
(n  65)
Fentanyl
(n  67)
Saline
(n  62)
Age, mean (SD), y 53.5 (11.1) 57.2 (10.1) 53.6 (9.5)
Sex, M : F, no. (%) 39 (60):26 (40) 39 (58):28 (42) 35 (56):27 (44)
Height, mean (SD), cm 165.0 (7.8) 162.2 (7.9) 163.0 (8.4)
Weight, mean (SD), kg 63.0 (10.4) 63.3 (9.6) 60.4 (8.9)
ASA status I/II, no. (%) 49 (75)/16 (25) 46 (72)/18 (28) 47 (77)/14 (23)
Hypertension, no. (%) 12 (18.5) 17 (25.4) 11 (17.7)
ASA  American Society of Anesthesiologists.
*No significant differences were found between the groups.
Table II. Incidence and grade of withdrawal movements associated with the rocuronium
injection. Data are shown as number (%) of patients.
Grade of Withdrawal
Movements*
Hydromorphone
(n  65)
Fentanyl
(n  67)
Saline
(n  62)
1 (No withdrawal) 63 (97.0)† 59 (92.2)† 25 (41.0)
(Wrist withdrawal) 1 (1.5) 1 (1.6) 5 (8.2)
(Arm withdrawal only) 0 (0) 2 (3.1) 20 (32.8)
(Generalized movement) 1 (1.5) 2 (3.1) 11 (18.0)
Proposed by Shevchenko et al.8
†P  0.001 versus the saline group.
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S.H. Lee et al.Figure 2. This figure delineates the (A) mean arterial pressure (MAP) and (B) heart rate (HR) on
arrival (baseline) and before (1min BI) and after (1min AI) tracheal intubation. This box
and whisker plot shows median values with interquartile ranges. There were statisti-
cally significant changes in the MAP and HR from the baseline after intubation in all
groups except for the changes in theMAPafter intubation in the hydromorphone group.
The MAP and HR after intubation in the fentanyl (median [interquartile range]) (101.5
[84115] mm Hg; 93.5 [82–102] beats per minute [bpm]) and hydromorphone (93.0
[83106] mmHg; 90.0 [86.393.6] bpm) groups were significantly lower than those
in the saline group (111.5 [105123] mm Hg; 103.5 [96113] bpm) (fentanyl group
MAP and HR: P< 0.001; hydromorphone group MAP and HR: P< 0.001). Baseline
upon arrival at the operating room; 1 min BI 1 minute before intubation; 1 min AI
1minute after intubation. *P values comparedwith the baseline valuewithin the group;
†P values compared with the saline group; ‡P values compared with the fentanyl group.
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Current Therapeutic Researchanalgesic effects to other opioids for acute pain.16 Despite its wide applications in
hronic and acute pain management, hydromorphone has not gained popularity in
re- or intraoperative use. MEDLINE was searched (inception to 2010) using the
ollowing terms: hydromorphone, induction, anesthesia, preoperative, intraoperative, and
nalgesia. The search did not identify any studies regarding the use of hydromorphone
s an adjuvant agent for general anesthesia.
In terms of onset of action, hydromorphone may not be appropriate for procedures
hat require a rapid onset time. Hydromorphone has an onset time of 5 minutes and
peak effect time of 10 to 20 minutes.17 Therefore, using hydromorphone as an
nduction adjuvant or pretreatment drug may be controversial. However, we found
hat patients in the hydromorphone group had effectively diminished rocuronium
njection pain within 90 seconds after injection and blunt cardiovascular responses to
racheal intubation with the same efficacy as fentanyl. This observation of instanta-
eous onset of pain subsidence to rocuronium injection may require explanations
ther than its centrally mediated analgesia, which take at least 5 minutes to be
ffective.
Opioid analgesia is obtained via the central and peripheral opioid receptors.2
The opioid receptors are found in peripheral terminals of the primary afferent
neurons18 as well as in the dorsal root ganglia19 and the central terminal of
rimary afferent nerves.20 The rocuronium injection pain has been attributed to
the direct activation of the C-nociceptor.4,5 It has been reported that venous
occlusion using a venous tourniquet may provide sufficient time for adequate
sequestration of pretreatment drugs; however, previous studies were conducted on
drugs, such as lidocaine, with local anesthetic properties.8 The venous occlusion
echnique may be applied to opioid pretreatment to assure its adequate seques-
ration within the vein and allow it to interact with the venous nociceptors.1,8
Table III. Incidence of patient movements, status of vocal cord relaxation during tracheal
intubation, and intubation time.
Hydromorphone
(n  65)
Fentanyl
(n  67)
Saline
(n  62)
Movement, no. (%) 12 (18.5) 12 (17.9) 20 (32.3)
Vocal cord relaxation full/
partial, no. (%) 59 (90.8)/6 (9.2) 61 (92.4)/5 (7.6) 52 (85.3)/9 (14.8)
Intubation time*, median
(interquartile range), sec 15 (1418) 15 (1318) 17 (1520)
P †P  0.060 †P  0.057
‡P  1.0
*Intubation time was defined as the time from mouth opening to obtaining an appropriate capnographic
trace.
†P values for intubation time compared with the saline group.
‡P values compared with the fentanyl group.Although this study did not use the venous occlusion technique while injecting
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may be one explanation for its prompt analgesic effects on rocuronium-induced
pain within 90 seconds in this study. Additional application of venous tourni-
quets in future studies could be performed to verify the peripheral analgesic
effects of hydromorphone. Therefore, if opioids with delayed onset displayed
prompt analgesic effect on injection followed by immediate rocuronium admin-
istration, peripheral analgesia of opioid may be suspected more prominently.
However, opioid pretreatments are used not only for reducing the withdrawal
movement but also to attenuate hemodynamic changes due to tracheal intubation.
Taking this into account, we used hydromorphone as the study agent to affect
rocuronium withdrawal movement and hemodynamic profile.
The status of vocal cord relaxation and the incidence of patient movement
during tracheal intubation showed no statistical difference among the 3 groups.
However, patients in the saline group presented more movements during intu-
bation than those in the hydromorphone and fentanyl groups. This finding may
suggest that despite the reportedly adequate muscle relaxation with rocuronium
0.6 mg/kg, adjuvant drugs, such as hydromorphone and fentanyl, are required to
deepen the level of anesthesia and suppress movement during the strong stimulus
of tracheal intubation. The time to facilitate intubation was different among the
groups (P  0.032); however, their differences of approximately 2 seconds are not
clinically significant.
The size and sites of the intravenous cannulas at 1 of the 6 superficial veins at the
forearm were not different among groups. By investigating the selection of the venous
cannulation at the forearm, it was expected that a difference in the withdrawal
movement according to the selection of veins would be detected, but without
significance.
This study had several limitations. First, there are no established recommended
doses of hydromorphone for the induction of anesthesia. Therefore, equianalgesic
doses of hydromorphone 0.03 mg/kg to fentanyl 2 g/kg were used. Because the
literature reports a hydromorphone-to-morphine equianalgesic potency of 1:5 to
1:7,12,13 a conversion ratio of 1:7 was used to select 0.03 mg/kg of hydromorphone.
t is possible that hydromorphone 0.03 mg/kg might have a lower or higher analgesic
ffect than fentanyl 2 g/kg. Second, the duration of hemodynamic monitoring was
ot long enough to fully evaluate the effects of hydromorphone on hemodynamic
tability. The maximum onset of action for hydromorphone is 10 to 20 minutes17;
therefore, a longer period of observation would have been appreciated. Third, the start
of sevoflurane after rocuronium injection is not congruent with common clinical
practice. This study was designed deliberately to turn sevoflurane on after rocuronium
injection to rule out any potential confounding effect of sevoflurane on withdrawal
movements. Fourth, hydromorphone is less emetogenic than the fentanyl deriva-
tives12,21,22; however, we did not observe the incidence or severity of postoperative
nausea and vomiting in this study.
Patients in the fentanyl and hydromorphone groups showed statistically significant
hemodynamic stability compared with patients in the saline group; however, the
45
c
d
c
Current Therapeutic Researchpatients in the latter group also did not show hemodynamic changes requiring
esmolol administration. Although withdrawal movement occurred significantly more
in patients in the saline group, it did not cause severe adverse outcomes such as loss
of intravenous cannulation, prolongation of intubation time, or loss of correct endo-
tracheal tube placement. In such respects, the benefits of using an opioid as a
pretreatment or adjuvant agent may be questionable; however, clinical implication
lies more in its use to debilitated patients in whom sympathetic stimulation might
cause detrimental clinical consequences, such as myocardial ischemia or hypertensive
events.23 Moreover, complications such as dislodgment of intravenous cannulation
in children or debilitated patients or pulmonary aspiration due to sudden with-
drawal movements could be life threatening even if occurring only rarely.24
Opioids, including fentanyl, are commonly used during induction with low or no
risk of side effects and potent effect of blunting sympathetic stimulation to
tracheal intubation25–28 or for reducing rocuronium injection pain.1,29 Therefore,
onsidering fentanyl or hydromorphone as an adjuvant or a pretreatment drug
uring induction may be prudent, especially in patients at risk of developing
ardiovascular events.
CONCLUSIONS
Compared with saline, hydromorphone produced immediate analgesia to rocuronium
paininduced withdrawal movement and reduced hemodynamic responses to tra-
cheal intubation. These findings were comparable with pretreatment with fentanyl.
These may be attributed both to central and peripheral antinociceptive effects of
opioids. Because using hydromorphone as an adjuvant agent during induction and the
intraoperative period is relatively novel, additional studies on the optimal use and
doses of hydromorphone during the induction of anesthesia and intraoperative periods
are needed.
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